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OBJECTIVE— Consumption of sugar-sweetened beverages (SSBs), which include soft
drinks, fruit drinks, iced tea, and energy and vitamin water drinks has risen across the globe.
Regular consumption of SSBs has been associated with weight gain and risk of overweight and
obesity, but the role of SSBs in the development of related chronic metabolic diseases, such as
metabolic syndrome and type 2 diabetes, has not been quantitatively reviewed.
RESEARCH DESIGN ANDMETHODS— We searched the MEDLINE database up to
May 2010 for prospective cohort studies of SSB intake and risk of metabolic syndrome and type
2 diabetes. We identified 11 studies (three for metabolic syndrome and eight for type 2 diabetes)
for inclusion in a random-effects meta-analysis comparing SSB intake in the highest to lowest
quantiles in relation to risk of metabolic syndrome and type 2 diabetes.
RESULTS— Based on data from these studies, including 310,819 participants and 15,043
cases of type 2 diabetes, individuals in the highest quantile of SSB intake (most often 1–2
servings/day) had a 26% greater risk of developing type 2 diabetes than those in the lowest
quantile (none or 1 serving/month) (relative risk [RR] 1.26 [95% CI 1.12–1.41]). Among
studies evaluating metabolic syndrome, including 19,431 participants and 5,803 cases, the
pooled RR was 1.20 [1.02–1.42].
CONCLUSIONS— In addition to weight gain, higher consumption of SSBs is associated
with development of metabolic syndrome and type 2 diabetes. These data provide empirical
evidence that intake of SSBs should be limited to reduce obesity-related risk of chronic metabolic
diseases.
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In recent decades, consumption of sug-ar-sweetened beverages (SSBs), whichinclude the full spectrum of soft drinks
(soda), fruit drinks, and energy and vita-
min water drinks has been steadily in-
creasing to various degrees across the
globe. For example, in the U.S. between
the late 1970s and 2006 the per capita
consumption of SSBs increased from 64.4
to 141.7 kcal/day, representing more than
a twofold increase (1). Similar temporal
patterns have been shown for Mexico,
where currently12% of total energy in-
take is contributed by these beverages (2).
Of particular concern is the rapid trajec-
tory of increase evident in many develop-
ing countries where access to SSBs has
grown concomitantly with rising rates of
urbanization. Sales figures from Coca Co-
la’s 2007 annual report show that during
2007, India and China experienced
growths of 14 and 18%, respectively, in
the volume of beverages sold, indicative
of substantial increases in sales at the pop-
ulation level (3).
SSBs, which are now the primary
source of added sugars in the U.S. diet, are
composed of energy-containing sweeten-
ers such as sucrose, high-fructose corn
syrup, or fruit juice concentrates, all of
which have essentially similar metabolic
effects (4). In contrast, a beverage that is
100% fruit juice and not blended with
added sweeteners is not considered an
SSB. Increasingly, groups of scholars and
organizations such as the American Heart
Association are calling for major reduc-
tions in consumption of SSBs (5,6). Find-
ings from well-powered prospective
epidemiological studies have shown con-
sistent positive associations between SSB
intake and weight gain and obesity in
both children and adults (7). Emerging
evidence also suggests that habitual SSB
consumption is associated with increased
risk of metabolic syndrome and type 2
diabetes (8). SSBs are thought to lead to
weight gain by virtue of their high sugar
content and incomplete compensation for
total energy at subsequent meals after in-
take of liquid calories (7). Because of the
high content of rapidly absorbable carbo-
hydrates such as sucrose (50% glucose
and 50% fructose) and high-fructose corn
syrup (most often 45% glucose and 55%
fructose), in conjunction with the large
volumes consumed, SSBs may increase
the risk of metabolic syndrome and type 2
diabetes not only through obesity but also
by increasing dietary glycemic load, lead-
ing to insulin resistance, -cell dysfunc-
tion, and inflammation (9). Additional
metabolic effects of these beverages may
also lead to hypertension and promote ac-
cumulation of visceral adipose tissue and
of ectopic fat due to elevated hepatic de
novo lipogenesis (10), resulting in the de-
velopment of high triglycerides and low
HDL cholesterol and small, dense LDL,
although the specific metabolic effects of
fructose versus glucose remain to be fur-
ther examined. To summarize the avail-
able literature, we conducted a meta-
analysis of prospective cohort studies to
examine the relationship between SSB
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Table 1—SSB intake and risk of type 2 diabetes and metabolic syndrome
Ref. Population (cases)
Age range
(years)
Duration
(years)
Dietary
assessment
method Outcome Results
Adjustment for potential
confounders
Montonen et al.,
2007 (14)
2,360 adults, Finnish
Mobile Clinic
Health
Examination,
Finland (177)
40–69 12 Diet
history
Type 2
diabetes*
RR (95% CI) between
extreme quartiles of
median SSB intake (0 vs.
143 g/day): 1.67 (0.98–
2.87); Ptrend  0.01
Age, sex, BMI, energy intake,
smoking, geographic area,
physical activity, family
history of diabetes,
prudent dietary score, and
conservative pattern score
Paynter et al.,
2006 (15)
12,204 adults ARIC
study, U.S. (718
men, 719 women)
45–64 9 FFQ Type 2
diabetes†
Men: RR (95% CI) between
extreme quartiles of SSB
intake (1 8-oz serving/
day vs. 2 8-oz
servings/day): 1.09
(0.89–1.33); Ptrend 
0.68. Women: RR (95%
CI) between extreme
quintiles of SSB intake:
1.17 (0.94–1.46);
Ptrend  0.05
Race, age
Schulze et al.,
2004 (16)
91,249 women NHS
II, U.S. (741)
24–44 8 133-item
FFQ
Type 2
diabetes†
RR (95% CI) between
extreme quartiles of SSB
intake (1
serving/month vs. 1
serving/day: 1.83 (1.42,
2.36); Ptrend  0.001
Age, alcohol intake, physical
activity, family history of
diabetes, smoking,
postmenopausal hormone
use, oral contraceptive
use, cereal fiber,
magnesium, trans fat, ratio
of polyunsaturated to
saturated fat, diet soft
drinks, fruit juice, fruit
punch
Palmer et al.,
2008 (17)
43,960 women
BWHS, U.S.
(2,713)
21–69 10 68-item
FFQ
Type 2
diabetes§
RR (95% CI) between
extreme quintiles of SSB
intake (1 12-oz
serving/month vs.  2
12-oz servings/day: 1.24
(1.06–1.45); Ptrend 
0.002
Age, family history of
diabetes, physical activity,
smoking, education, fruit
drinks, orange and
grapefruit juice, fortified
fruit drinks, Kool-Aid,
other fruit juices, red
meat, processed meat,
cereal fiber, coffee and
glycemic index
Bazzano et al.,
2008 (18);
author
correspondence
71,346 women NHS,
U.S. (4,529)
38–63 18 FFQ Type 2
diabetes‡
RR (95% CI) between
extreme quintiles of SSB
intake: (1 12-oz
serving/month vs. 2–3
12-oz servings/day):
1.31 (0.99–1.74);
Ptrend  0.001
BMI, physical activity, family
history of diabetes,
postmenopausal hormone
use, alcohol use, smoking,
and total energy intake
Odegaard et al.,
2010 (19)
43,580 adults,
Singapore Chinese
Health study
(2,273)
45–74 5.7 FFQ Type 2
diabetes‡
RR (95% CI) between
extreme quintiles of SSB
intake: (none vs. 2
8-oz servings/week):
1.42 (1.25–1.62);
Ptrend  0.0001
Age, sex, dialect, year of
interview, educational
level, smoking, alcohol,
physical activity, saturated
fat, dietary fiber, dairy,
juice, coffee
De Koning, 2010,
personal
communication
41,109 male health
professionals, U.S.
(2,760)
40–75 20 FFQ Type 2
diabetes†
RR (95% CI) between
extreme quartiles of
median SSB intake (0 vs.
0.79 serving/day): 1.14
(1.03–1.28); Ptrend 
0.0024
Age, smoking, physical
activity, alcohol, coffee,
family history of type 2
diabetes
(continued)
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consumption and risk of developing met-
abolic syndrome and type 2 diabetes.
RESEARCH DESIGN AND
METHODS
Literature search
Relevant English-language articles were
identified by searching the MEDLINE da-
tabase (National Library of Medicine, Be-
thesda, MD) from 1966 to May 2010 for
prospective cohort studies of intake of
SSBs (soft drinks, carbonated soft drinks,
fruitades, fruit drinks, sports drinks, en-
ergy and vitamin water drinks, sweetened
iced tea, punch, cordials, squashes, and
lemonade) and risk of metabolic syn-
drome and type 2 diabetes in adults. Key
words such as “soda,” “soda-pop,” and
“sugar-sweetened beverage” combined
with “diabetes,” “type 2 diabetes,” and
“metabolic syndrome” were used in the
primary search strategy and in a subse-
quent medical subheading (MESH) terms
search. Because of the high potential for
intractable confounding and reverse cau-
sation, cross-sectional studies were ex-
cluded. We did not consider short-term
experimental studies because they are not
well-suited to capture long-term patterns,
but rather provide important insight into
potential underlying biological mecha-
nisms. Our literature search identified 15
studies with metabolic syndrome as an
end point and 136 studies with type 2
diabetes as an end point. An additional
study of type 2 diabetes by de Koning and
colleagues was identified via personal
communication.
Inclusion criteria and data
extraction
The criteria for inclusion of studies in our
meta-analysis included prospective co-
hort design, end points of metabolic syn-
drome or type 2 diabetes, presentation of
a relative risk (RR) and associated mea-
sure of variance (SE or 95% CI), defini-
tion, and metric for SSB intake and
description of adjustment for potential
confounders. After application of these
criteria, three studies of metabolic syn-
drome (11–13) and eight studies of type 2
diabetes (11,14 –19) were retained for
our meta-analysis. Coefficients and SEs
were obtained from Nettleton et al. (11)
and Bazzano et al. (18) via correspon-
dence. Data extraction was independently
performed by V.S.M. and F.B.H., and
there were no differences in extracted in-
formation to yield effect estimates com-
paring extreme quantiles of intake, most
often comparing none or 1 serving/
month with 1 or 2 servings/day. Nota-
ble exceptions include Odegaard et al.
(19) in which the highest category of in-
Table 1—Continued
Ref. Population (cases)
Age range
(years)
Duration
(years)
Dietary
assessment
method Outcome Results
Adjustment for potential
confounders
Nettleton et al.,
2009 (11);
author
correspondence
5,011 adults, MESA,
U.S. (413)
45–84 5 FFQ Type 2
diabetes
RR (95% CI) between
extreme quartiles of SSB
intake (0 vs. 1 serving/
day): 0.86 (0.62–1.17);
Ptrend  0.09
Study site, age, sex, race,
energy intake, education,
physical activity, smoking,
at least weekly
supplement use, waist
circumference
Nettleton et al.,
2009 (11);
author
correspondence
3,878 adults, MESA,
U.S. (871)
45–84 5 FFQ Metabolic
syndrome¶
RR (95% CI) between
extreme quartiles of SSB
intake (0 vs.  1
serving/day): 1.15
(0.92–1.42); Ptrend 
0.65
Study site, age, sex, race,
energy intake, education,
physical activity, smoking,
at least weekly
supplement use, waist
circumference
Dhingra et al.,
2007 (13)
6,039 adults,
Framingham
Offspring Study,
U.S.A. (1,150)
52.9 4 FFQ Metabolic
syndrome#
RR (95% CI) between
extreme quartiles of soft
drink intake (0 vs. 1
12-oz serving/day): 1.39
(1.21–1.59)**
Age and sex
Lutsey et al., 2008
(12)
9,514 adults ARIC,
U.S. (3,782)
45–64 9 66-item
FFQ
Metabolic
syndrome¶
RR (95% CI) between
extreme tertiles of SSB
intake (0 vs. 1 median
serving/day): 1.09
(0.99–1.19); Ptrend 
0.07
Age, sex, race, education,
center, total calories,
smoking, physical activity,
intake of meat, dairy,
fruits and vegetables,
whole grains, and refined
grains
ARIC, Atherosclerosis Risk in Communities Study; BWHS, Black Women’s Health Study; MESA, Multi-Ethnic Study of Atherosclerosis; NHS, Nurses’ Health Study.
*National register confirmed by medical record. †Presence of one of the following: 1) fasting glucose126 mg/dl, 2) nonfasting glucose200 mg/dl, 3) current use
of hypoglycemic medication, and 4) self-report physician diagnosis. ‡Self-report of physician diagnosis and supplemental questionnaire. §Confirmed self-report of
physician diagnosis. Presence of one of the following: 1) fasting glucose 126 mg/dl, 2) current use of hypoglycemic medications; and 3) self-report physician
diagnosis. ¶Metabolic syndrome diagnosed according to the modified National Cholesterol Education Program Adult Treatment Panel III criteria/American Heart
Association guidelines as the presence of three or more of the following: 1) waist circumference102 (men) or88 cm (women), 2) triglycerides150 mg/dl, 3)
HDL cholesterol 40 (men) or 50 mg/dl (women), 4) blood pressure 130/85 mmHg or antihypertensive treatment, and 5) fasting glucose 100 mg/dl or
antihyperglycemic treatment/insulin. #Metabolic syndrome diagnosed according to the modified National Cholesterol Education Program Adult Treatment Panel III
definition/American Heart Association guidelines as the presence of three or more of the following: 1) waist circumference 102 (men) or 88 cm (women), 2)
triglycerides150 mg/dl, 3) HDL cholesterol40 (men) or50 mg/dl (women), 4) blood pressure135/85 mmHg or antihypertensive treatment, and 5) fasting
glucose 100 mg/dl or antihyperglycemic treatment/insulin. **Includes diet and nondiet soft drinks.
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take was 2–3 8-oz servings/week, Mon-
tonen et al. (14) in which the comparison
between median intakes of the first and
fourth quartiles was 0 vs. 143 g/day (note:
one 12-oz serving  336 g), and Paynter
et al. (15) in which 1 8-oz serving/day
was the reference category. Unless other-
wise specified a standard serving size of
12 oz was the metric used.
Analysis
A total of eight studies with nine data
points were included in our meta-analysis
of type 2 diabetes (11,14–19) and three
studies were included in our meta-
analysis of metabolic syndrome (11–13).
STATA (version 9.0; StataCorp, College
Station, TX) was used to obtain summary
RRs using both random- and fixed-effects
models calculated from the logarithm of
the RRs and corresponding 95% CIs of
the individual studies. We primarily used
a random-effects model because it incor-
porates both a within-study and an addi-
tive between-studies component of
variance, is the accepted method to use in
the presence of between-study heteroge-
neity, and is generally considered the
more conservative method (20). Signifi-
cance of heterogeneity of study results
was evaluated using the Cochrane Q test,
which has somewhat limited sensitivity,
and further by the I2 statistic, which rep-
resents the percentage of total variation
across studies that is due to between-
study heterogeneity (21). Because adjust-
ment for total energy intake and duration
of follow-up could be important sources
of heterogeneity, we conducted indepen-
dent meta-regressions using adjustment
for energy and study duration as predic-
tors of effect. Because the association be-
tween SSB consumption and these
outcomes is likely to be mediated in part
by an increase in overall energy intake or
adiposity, adjusting for these factors is ex-
pected to attenuate the effect. Where pos-
sible we used estimates that were not
adjusted for energy intake or adiposity
and conducted sensitivity analysis by re-
moving studies that only provided ener-
gy- or adiposity-adjusted estimates. The
potential for publication bias was evalu-
ated using Begg and Egger tests and visual
inspection of the Begg funnel plot
(22,23).
RESULTS— Characteristics of the
prospective cohort studies included in
our meta-analyses are shown in Table 1.
Three studies evaluated risk of metabolic
syndrome (11–13) and eight studies
(nine data points) evaluated risk of type 2
diabetes (11,14 –19). The cohorts in-
cluded men and women of predominately
white or black populations from the U.S.,
adults from Finland, and Chinese adults
from Singapore, with duration of fol-
low-up ranging from 4 to 20 years and
number of participants ranging from
3,000 to 91,000. The majority of
studies used food frequency question-
naires (FFQs) to evaluate dietary intake
and six studies (seven data points) (13,
15–17, 19) provided effect estimates that
were not adjusted for total energy or mea-
sures of adiposity. Based on data from
these studies, including 310,819 partici-
pants and 15,043 cases of type 2 diabetes,
the pooled RR for type 2 diabetes was
1.26 (95% CI 1.12–1.41) comparing ex-
treme quantiles of SSB intake, illustrating
an excess risk of 26% associated with
higher consumption of SSB compared
with lower consumption (Fig. 1A).
Among three studies evaluating metabolic
syndrome including 19,431 participants
and 5,803 cases, the pooled RR was 1.20
(1.02–1.42) (Fig. 1B). Pooled RR esti-
mates from the fixed-effects model were
1.25 (1.17–1.32) and 1.17 (1.09–1.26)
for type 2 diabetes and metabolic syn-
drome, respectively. Results from a dose-
response meta-analysis for type 2 diabetes
risk per increase in 1 12-oz serving of SSB/
day were RR 1.25 (95% CI 1.10–1.42)
from the random-effects model and RR
1.15 (95% CI 1.11–1.20) from the fixed-
effects model (not shown).
Although all studies except one (11)
showed positive associations, there was
significant heterogeneity among studies
Figure 1—A: Forrest plot of studies evaluating SSB consumption and risk of type 2 diabetes,
comparing extreme quantiles of intake. Random-effects estimate (DerSimonian and Laird
method). *Information from personal communication. B: Forrest plot of studies evaluating SSB
consumption and risk of metabolic syndrome comparing extreme quantiles of intake. Random-
effects estimate (DerSimonian and Laird method).
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in both analyses (for type 2 diabetes: I2
66% [95% CI 31–83%], P value, test for
homogeneity 0.003; for metabolic syn-
drome: 76% [22–93%]; P value, test for
homogeneity 0.01). In general, larger
studies with longer durations of fol-
low-up tended to show stronger associa-
tions. Among studies evaluating type 2
diabetes, the one by Nettleton et al. (11) is
both the shortest and among the smallest,
and the only one to show an inverse al-
though nonsignificant association (11).
Removal of this study from our analysis
only reduced heterogeneity slightly (I2
62% [95% CI 17–82%], P value, test for
homogeneity 0.01). In contrast, studies
by Schulze et al. (16) and Palmer et al.
(17), which are longer and larger, show
clearly significant positive associations.
Despite this, results from a meta-
regression did not find duration of study
to be a significant predictor of effect (P
0.84). The study by Montonen et al. (14),
which shows a borderline significant pos-
itive association, has the fewest number of
participants and considerably lower levels
of intake relative to those of other studies
(median intake of SSB is 143 g/day in
highest quartile of intake, where one
12-oz serving is 336 g). Removal of this
study from our analysis did not reduce
heterogeneity, which is to be expected,
given its small percentage weight (P value,
test for homogeneity 0.002). The study by
Schulze et al. (16), which is the largest
and which used repeated measures of SSB
intake, reported the strongest study-
specific estimate. Removal of this study
from the pooled analysis reduced hetero-
geneity to borderline significance (I2 51%
[95% CI 0–78%]; P value, test for homo-
geneity 0.05). Tests for publication bias
generally rely on the assumption that
small studies (large variance) may be
more prone to publication bias, com-
pared with larger studies. Visual inspec-
t ion of the Begg funne l p lo t
(supplementary Fig. 1A and B, available
in an online appendix at http://care.
diabetesjournals.org/cgi/content/full/dc10-
1079/DC1), whereby the SE of log RR
(measure of study size) from each study
was plotted against the log RR (treatment
effect), showed symmetry about the plot,
suggesting that publication bias is un-
likely, although values for metabolic
syndrome may not be particularly infor-
mative because of the small number of
studies included in the analysis. Studies
with a large SE and large effect may sug-
gest the presence of a small-study effect
(the tendency for smaller studies in a
meta-analysis to show larger treatment ef-
fects). Results from the Begg (type 2 dia-
betes P 0.75; metabolic syndrome P
1.0) and Egger (type 2 diabetes P 0.75;
metabolic syndrome P  0.72) tests also
suggest that publication bias is unlikely.
Because the association between SSB
consumption and risk of these disease
outcomes is mediated in part by energy
intake and adiposity, adjustment for these
factors will tend to underestimate any ef-
fect. Results from our sensitivity analysis
in which energy- and adiposity-adjusted
coefficients were excluded (11,14,18)
showed a slight increase in risk of type 2
diabetes with a pooled RR of 1.28 (95%
CI 1.13–1.45) from the random-effects
model and RR 1.25 (1.18–1.34) from the
fixed-effects model. A greater magnitude
of increase was noted in the dose-
response meta-analysis when these stud-
ies (11,14,18) were excluded: RR 1.35
(1.14 –1.59) and RR 1.18 (1.12–1.24)
from the random and fixed-effects mod-
els, respectively. However, results from a
meta-regression did not find adjustment
for energy to be a significant predictor of
effect (P 0.38). Sensitivity analysis was
not possible for studies of metabolic syn-
drome because they are too few in num-
ber; however, both studies that adjusted
for these potential mediators of effect had
marginal nonsignificant associations
(11,12), whereas the study that reported
unadjusted estimates showed a strong
positive association (13).
CONCLUSIONS— Findings from
our meta-analyses show a clear link be-
tween SSB consumption and risk of met-
abolic syndrome and type 2 diabetes.
Based on coefficients from three prospec-
tive cohort studies including 19,431 par-
ticipants and 5,803 cases of metabolic
syndrome, participants in the highest cat-
egory of intake had a 20% greater risk of
developing metabolic syndrome than
those in the lowest category of intake. For
type 2 diabetes, based on data from eight
prospective cohort studies (nine data
points), including 310,819 participants
and 15,043 cases of type 2 diabetes, par-
ticipants in the highest category of SSB
intake had a 26% greater risk of develop-
ing type 2 diabetes than participants in
the lowest category of intake.
Because we compared extreme quan-
tiles of SSB intake, most often none or1
serving/month with1 or 2 servings/day,
categories of intake between studies were
not standardized. Therefore, it is possible
that random misclassification somewhat
attenuated the pooled estimate; however,
results were similar to the dose-response
analysis, which used data from all catego-
ries. For those studies that did not define
serving size, a standard serving of 12 oz
was assumed, which may over- or under-
estimate empirical SSB intake levels but
should not materially affect our results.
Indeed there is substantial variation in
study design and exposure assessment,
across studies, which may explain the
large degree of between-study heteroge-
neity we observed. Meta-analyses are in-
herently less robust than individual
prospective cohort studies but are useful
in providing an overall effect size, while
giving larger studies and studies with less
random variation greater weight than
smaller studies. Publication bias is always
a potential concern in meta-analyses, but
standard tests and visual inspection of
funnel plots suggested no evidence of
publication bias in our analysis. Ascer-
tainment of unpublished results may have
reduced the likelihood of publication
bias. Because our analysis compared only
the top with the bottom categories, we did
not use data from the intermediate cate-
gories. Thus, the comparison of extreme
categories was not statistically significant
for the studies of Montonen et al. (14),
Paynter et al. (women) (15), and Bazzano
et al. (18), even though the overall tests
for trend in these studies were significant.
All studies included in our meta-
analysis considered adjustment for poten-
tial confounding by various diet and
lifestyle factors, and for most a positive
association persisted, suggesting an inde-
pendent effect of SSBs. However, residual
confounding by unmeasured or imper-
fectly measured factors cannot be ruled
out. Higher levels of SSB intake could be a
marker of an overall unhealthy diet as
they tend to cluster with factors such as
higher intakes of saturated and trans fat
and lower intake of fiber (12). Therefore,
incomplete adjustment for various diet
and lifestyle factors could overestimate
the strength of the positive association be-
tween SSB intake and risk of metabolic
syndrome and type 2 diabetes. However,
consistency of results from different co-
horts reduces the likelihood that residual
confounding is responsible for the find-
ings. Longitudinal studies evaluating diet
and chronic disease risk may also be
prone to reverse causation, i.e., individu-
als change their diet because of symptoms
of subclinical disease or related weight
gain, which could result in spurious asso-
ciations (24). Although it is not possible
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to completely eliminate these factors,
studies with longer durations of fol-
low-up and repeated measures of dietary
intake tend to be less prone to this
process.
In several studies, type 2 diabetes was
assessed by self-report; however, it has
been shown in validation studies that self-
report of type 2 diabetes is highly accurate
according to medical record review (25).
The majority of studies used validated
FFQs to measure SSB intake, which is the
most robust method for estimating an in-
dividual’s average dietary intake com-
pared with other assessment methods
such as 24-h diet recalls (26). However,
measurement error in dietary assessment
is inevitable, but because the studies we
considered are prospective in design, mis-
classification of SSB intake probably does
not differ by case status. Such nondiffer-
ential misclassification of exposure is
likely to underestimate the true associa-
tion between SSB intake and risk of these
outcomes.
SSBs are thought to lead to weight
gain by virtue of their high added sugar
content, low satiety potential and incom-
plete compensatory reduction in energy
intake at subsequent meals after con-
sumption of liquid calories, leading to
positive energy balance (7,8). Although
SSBs increase risk of metabolic syndrome
and type 2 diabetes, in part because of
their contribution to weight gain, an in-
dependent effect may also stem from the
high levels of rapidly absorbable carbohy-
drates in the form of added sugars, which
are used to flavor these beverages. The
findings by Schulze et al. (16) suggested
that approximately half of the effects of
SSBs on type 2 diabetes were mediated
through obesity. In a recent study among
88,000 women followed for 24 years,
those who consumed 2 SSBs/day had a
35% greater risk of coronary heart disease
compared with infrequent consumers af-
ter adjustment for other unhealthy life-
style factors (RR 1.35 [95% CI 1.1–1.7,
Ptrend  0.01) (27). Additional adjust-
ment for potential mediating factors in-
cluding BMI, total energy, and incident
type 2 diabetes attenuated the associa-
tions, but they remained statistically sig-
nificant, suggesting that the effect of SSBs
is not entirely mediated by these factors.
Because SSBs have been shown to
raise blood glucose and insulin concen-
trations rapidly and dramatically (28) and
are often consumed in large amounts,
they contribute to a high dietary glycemic
load. High glycemic load diets are known
to induce glucose intolerance and insulin
resistance particularly among overweight
individuals (9) and can increase levels of
inflammatory biomarkers such as C-reac-
tive protein, which are linked to type 2
diabetes risk (29). Findings from our co-
horts indicate that a high dietary glycemic
load also increases risk of developing cho-
lesterol gallstone disease, which is associ-
ated with insulin resistance, metabolic
syndrome, and type 2 diabetes (30). En-
dogenous compounds in SSBs, such as
advanced glycation end products, pro-
duced during the process of carameliza-
tion in cola-type beverages may also affect
pathophysiological pathways related to
type 2 diabetes and metabolic syndrome
(31). SSBs may also increase risk indi-
rectly by inducing alterations in taste
preferences and diet quality, resulting
from habitual consumption of highly
sweetened beverages, which has also been
noted for artificially sweetened beverages
(5).
Short-term experimental studies sug-
gest that fructose, which is a constituent
of both sucrose and high-fructose corn
syrup in relatively equal parts, may exert
particularly adverse metabolic effects
compared with glucose. Fructose is pref-
erentially metabolized to lipid in the liver,
leading to increased hepatic de novo lipo-
genesis, the development of high triglyc-
erides, low HDL cholesterol, small, dense
LDL, atherogenic dyslipidemia, and insu-
lin resistance (32). Recent evidence has
also shown that fructose consumption
may promote accumulation of visceral ad-
iposity or ectopic fat deposition (10), two
key features of a dysmetabolic state in-
creasing risk of type 2 diabetes and car-
diovascular disease (33), despite no
difference in weight gain between glucose
and fructose conditions (10). In contrast,
some studies have shown greater satiety
and lower total energy intake after intake
of fructose-containing beverages com-
pared with glucose beverages (34). Gha-
nim et al. (35) found evidence of
oxidative and inflammatory stress after
intake of glucose but not fructose or or-
ange juice. However, fructose has also
been shown to increase blood pressure
when administered acutely or when con-
sumed as SSBs, an effect not observed
with glucose administration or consump-
tion of aspartame-sweetened beverages
(36,37). A number of prospective cohort
studies have found positive associations
between SSB consumption and incident
hypertension (11,13). Fructose is also the
only sugar able to increase blood uric acid
concentrations, and SSB consumption
has been linked to development of hyper-
uricemia (serum uric acid level7 mg/dl
for men and5.7 mg/dl for women) (38)
and gout (39). Men who consumed 2
SSBs/day had an 85% greater risk of de-
veloping gout compared with infrequent
consumers (RR 1.85 [95% CI 1.08–3.16];
Ptrend  0.001 for trend). No association
was shown with diet soda. A recent ran-
domized controlled trial among men in
Spain showed that high doses of fructose
increased blood pressure and induced
features of metabolic syndrome and that
pharmacologically lowering uric acid lev-
els prevented the increase in mean arterial
blood pressure (40).
In summary, this meta-analysis has
demonstrated that higher consumption of
SSBs is significantly associated with de-
velopment of metabolic syndrome and
type 2 diabetes. It provides further sup-
port to limit consumption of these bever-
ages in place of healthy alternatives such
as water to reduce obesity-related chronic
disease risk.
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